AYTU BIOPHARMA, INC Accretion Expense
AYTU BIOPHARMA, INC (AYTU) reported Accretion Expense of $23.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-05-16
- AYTU BIOPHARMA, INC accretion expense for the quarter ending 2022-03-31 was $23.00K, a 53.33% increase year-over-year.
- AYTU BIOPHARMA, INC accretion expense for the quarter ending 2021-12-31 was $22.00K, a 92.67% decline year-over-year.
- AYTU BIOPHARMA, INC accretion expense for the quarter ending 2021-09-30 was $34.00K, a 88.67% decline year-over-year.
- AYTU BIOPHARMA, INC accretion expense for the quarter ending 2021-03-31 was $15.00K.
- AYTU BIOPHARMA, INC accretion expense for fiscal 2016 was $6.00M, a 0.00% change from fiscal 2015.
- AYTU BIOPHARMA, INC accretion expense for fiscal 2015 was $6.00M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $23.00K 10-Q · filed 2022-05-16 | $45.00K derived: sum of 2 quarters · filed 2022-05-16 | $100.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $22.00K 10-Q · filed 2022-02-14 | $100.00K 10-Q · filed 2022-02-14 | ||
| 2021-09-30 | $34.00K 10-Q · filed 2021-11-15 | |||
| 2021-03-31 | $15.00K 10-Q · filed 2022-05-16 | $315.00K derived: sum of 2 quarters · filed 2022-05-16 | $300.00K 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $300.00K 10-Q · filed 2022-02-14 | $300.00K 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-15 | |||
| 2017-03-31 | $3.94M 10-Q · filed 2017-05-11 | |||
| 2016-06-30 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $6.00M 10-K · filed 2017-08-31 | ||
| 2016-03-31 | $3.94M 10-Q · filed 2017-05-11 | |||
| 2015-06-30 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01 | $6.00M 10-K · filed 2016-09-01 | ||
| 2015-03-31 | $3.94M 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |